SINGAPORE - Singapore is set to receive its due share of the deluge of investments flowing into the research and development of new drugs, including mRNA-based vaccines and therapies.
While mRNA vaccines have earned validation through coronavirus jabs, the future of the breakthrough technology they represent goes beyond Covid-19 itself, said Singapore-based David Peacock, who was appointed last month as the Asia-Pacific president of MSD, the international trade name of American pharma giant Merck & Co.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
